202979-48-4

Upstream product

• 208767-18-4 (E)-(2R,3S)-3-Benzyloxymethyl-2-tert-butoxycarbonylamino-6-(tert-butyl-diphenyl-silanyloxy)-hex-4-enoic acid 
• 208767-19-5 [(E)-(S)-2-Benzyloxymethyl-5-(tert-butyl-diphenyl-silanyloxy)-pent-3-enyl]-carbamic acid tert-butyl ester 
• 67-64-1 acetone 
• 208767-20-8 [(2S,3R,4R)-2-Benzyloxymethyl-5-(tert-butyl-diphenyl-silanyloxy)-3,4-dihydroxy-pentyl]-carbamic acid tert-butyl ester 

Downstream Products

• 202979-50-8 (3aR,7S,7aR)-7-Benzyloxymethyl-2,2-dimethyl-hexahydro-[1,3]dioxolo[4,5-c]pyridine 
• 202979-49-5 [(S)-3-Benzyloxy-2-((4R,5R)-5-hydroxymethyl-2,2-dimethyl-[1,3]dioxolan-4-yl)-propyl]-carbamic acid tert-butyl ester 

Relevant academic research and scientific papers

Synthesis of 5-epi-isofagomine via asymmetric chelate-enolate Claisen rearrangement

Polyhydroxylated piperidines are an interesting class of glycosidase inhibitors. Chelate enolate Claisen rearrangement of N-protected chiral amino acid esters gives rise to γ,δ-unsaturated amino acids, which can be converted to this type of alkaloids. The

Application of the asymmetric chelate-enolate Claisen rearrangement to the synthesis of 5-epi-isofagomine

Chelate-enolate Claisen rearrangement of a N-protected chiral amino acid ester gave rise to a γ,δ-unsaturated amino acid, which could be converted to the potential glycosidase inhibitor 5-epi-isofagomine (9) in a straightforward and a highly stereoselecti